Tag: Gastric Cancer
-
SU2C Dream Team Targets Early Detection of Gastric Cancer: A Global Push for Prevention
Overview: A Global Mission Against Gastric Cancer Stand Up To Cancer (SU2C) and Cancer Research UK have launched a bold, global effort to halt gastric cancer at its earliest stages. A newly formed dream team brings together leading scientists, clinicians, and patient advocates from multiple countries to accelerate discoveries that could transform prevention, screening, and…
-
SU2C Dream Team Aims to Detect Gastric Cancer Early with Global Prevention Trial
Global Collaboration to Tackle Gastric Cancer Early Stand Up To Cancer (SU2C) and Cancer Research UK announced a bold new initiative: a dream team dedicated to stopping gastric cancer in its tracks by focusing on early detection and prevention. The international effort brings together leading researchers from multiple countries who will collaborate on a gastric…
-
SU2C Dream Team Targets Early Detection of Gastric Cancer: Global Clinical Trial on the Horizon
New Frontiers in Gastric Cancer Prevention Stand Up To Cancer (SU2C) and Cancer Research UK (CRUK) have announced a bold new initiative aimed at transforming the fate of gastric cancer through early detection. The newly formed SU2C dream team brings together leading researchers from around the world to accelerate breakthroughs in identifying gastric cancer at…
-
HUTCHMED Wins Priority NDA Acceptance in China for Savolitinib-Based MET Inhibition Therapy
HUTCHMED Advances Savolitinib with Priority NDA Acceptance in China HUTCHMED, a global biopharma company focused on oncology and immunology, announced that the National Medical Products Administration (NMPA) in China has accepted its new drug application (NDA) for Savolitinib with priority review status. This move follows the company’s recent positive Phase II registration study data in…
-
Hutchmed Wins Priority NDA Acceptance in China for Savolitinib After Positive Phase II Data
Overview: Hutchmed Moves Forward with Savolitinib in China Hutchmed (Hydrogenated Medicine) has announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Savolitinib with priority review. This milestone follows a sequence of supportive data, including a positive Phase II registration study conducted in Chinese patients and a 2023 Breakthrough…
-
Early Signs of Stomach Cancer: What to Watch For and When to Seek Help
Understanding Stomach Cancer and Its Early Phases Stomach cancer, also known as gastric cancer, tends to develop slowly over many years. In its initial stages, the changes happening in the stomach lining often cause little to no noticeable symptoms. That’s why awareness of potential early signs is important for timely evaluation and treatment if needed.…
-
Recognizing the Early Signs of Stomach Cancer: What to Watch For
Understanding Stomach Cancer and Its Early Changes Stomach cancer, or gastric cancer, often develops slowly over several years. In its earliest stages, the changes within the stomach lining may be present but cause few, if any, noticeable symptoms. Because these early changes can be subtle, many people do not seek medical evaluation until the cancer…
-
Stomach Cancer in Portugal: North Leads Western Europe
Overview: Stomach Cancer in Portugal World Digestive Cancer Day, observed on September 30, shines a light on stomach cancer, a disease that remains a pressing public health challenge in Portugal. The latest data from GLOBOCAN 2022 show that Portugal registered more than 18,000 new cases and about 11,700 deaths that year, equivalent to roughly 30…